Walsh TJ, Coleman CI, Blissett R, Prawitz T, et al. Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective. Antimicrob Agents Chemother 2025 Aug 27:e0057025. doi: 10.1128/aac.00570.
PMID: 40863562